Avanafil API EU

Avanafil is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor used for the treatment of erectile dysfunction (ED). It is a small molecule drug that acts by blocking the PDE5 enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP), a critical signaling molecule involved in penile smooth muscle relaxation and blood flow regulation.

Avanafil has a rapid onset of action, with peak plasma concentrations reached within 30-45 minutes after oral administration. Its half-life is approximately 5 hours, which allows for flexible dosing and sexual spontaneity. Avanafil is rapidly absorbed and extensively metabolized in the liver, primarily via the cytochrome P450 (CYP) 3A4 pathway.

Avanafil is available in tablet form and is typically prescribed in dosages ranging from 50 mg to 200 mg, depending on individual patient characteristics and response to treatment. The recommended starting dose is 100 mg, taken orally approximately 30 minutes before sexual activity. The maximum recommended dosing frequency is once per day.

Avanafil is generally well-tolerated, with the most common side effects being headache, flushing, nasal congestion, and back pain. Rare but serious adverse events include sudden vision loss, hearing loss, and priapism (prolonged erection lasting more than 4 hours). Avanafil should not be used in patients taking nitrates, alpha-blockers, or other medications that interact with the CYP3A4 pathway.

Avanafil has been extensively studied in clinical trials involving thousands of patients with ED, demonstrating significant improvements in erectile function, intercourse satisfaction, and overall sexual satisfaction compared to placebo. Avanafil has also been shown to be effective in patients with diabetes, hypertension, and other comorbidities commonly associated with ED.

In summary, Avanafil is a potent and selective PDE5 inhibitor used for the treatment of ED. Its rapid onset of action, flexible dosing, and tolerable side effect profile make it an attractive treatment option for patients with ED. However, as with all medications, it should be used under the guidance and supervision of a healthcare professional.